The first GLP-1 tracker built for the oral pill era — every injection app has a feature gap.
Oral Wegovy (semaglutide pill) was approved by the FDA on December 22, 2025 and reached US pharmacies in January 2026. A second oral GLP-1 — Orforglipron (Foundayo, Eli Lilly) — was approved in April 2026 and requires no fasting window. The shift from weekly injection to daily oral pill is underway, and no tracker app has been rebuilt to match it.
Injection trackers log one event per week. Oral GLP-1 users need: a 30-minute fasting window reminder every morning, daily protein-first nudges to prevent muscle loss, and a completely different cadence UI. Bolting "pill mode" onto an injection app — as Shotsy did in March 2026 — is the wrong architecture.
| Segment | Size (2025) | CAGR | Source |
|---|---|---|---|
| Global GLP-1 Drug Market | $62.8B – $94B | ~35% (oral segment) | Multiple pharma analysts, 2025 |
| Weight Loss App Market | $1.15B | 17.4% YoY | Grand View Research, 2025 |
| Oral GLP-1 Market (2026–2035) | Nascent | 35.05% CAGR | Industry projections, 2026 |
| Americans on GLP-1s (2026) | 10–12.4M | → 25M by 2030 | KFF / Trilliant Health, 2025 |
Oral semaglutide prescriptions are up +50% since December 2025. Shotsy added a basic pill mode in March 2026 (v3.0) — but the UI is injection-first and the pill features are bolted on. The window to launch a purpose-built oral GLP-1 tracker is open right now. First-mover advantage in a category shaped by prescription volume accrues to whoever ships earliest.
Five competitors mapped against the six features that matter most for oral GLP-1 users. GlpDay is the only app that ships all six natively.
| App | Pill-Native UI | Fasting Window Reminder | Protein-First Nudges | Muscle Tracking | Price / yr | On-Device Privacy |
|---|---|---|---|---|---|---|
| GlpDay | Yes — built for pills | Yes — 30-min window | Yes — daily nudges | Yes — unique feature | $29.99 | HealthKit on-device |
| Shotsy | Partial — bolt-on v3.0 | No | No | No | $69.99 | Unverified |
| MeAgain | No | No | No | No | $119.88 | Unverified |
| Noom | No | No | No | No | $209.00 | Cloud-dependent |
| WeightWatchers | No | No | No | No | $382.68 | Cloud-dependent |
| Lark Health Coach | No | No | No | No | B2B only | Enterprise |
The fasting window reminder + protein nudges + muscle tracking combination does not exist in any current App Store app. This is a genuine product gap, not a marketing positioning gap.
At $29.99/yr, GlpDay is the lowest-priced dedicated GLP-1 tracker by a significant margin. Shotsy raised its price 133% in 2025 — from $29.99/yr to $69.99/yr — with no meaningful new features for oral users, creating a clear price-to-value gap for GlpDay to exploit.
GlpDay users save $120 vs Shotsy over 3 years while getting pill-native UX, fasting window reminders, protein nudges, and muscle tracking that Shotsy doesn't have. The price-to-value argument writes itself.
Shotsy was the dominant GLP-1 tracker for weekly injection users (Ozempic, Wegovy syringe). Clean UI, dose logging, refill reminders. Became the default choice for injection-based GLP-1 patients. Strong 4.5-star rating reflects genuine product quality for its original use case.
Shotsy raised its annual price from $29.99 to $69.99 — a 133% increase — without shipping features that meaningfully serve oral GLP-1 users. Pill mode (v3.0, March 2026) is bolted onto an injection-first UI. The pricing move has created visible user backlash and a clear opening for GlpDay.
Shotsy's v3.0 pill mode is architecturally compromised. The onboarding flow starts with "What injection are you on?" The daily view still shows a weekly injection timeline. There is no fasting window reminder. The app was not rebuilt for daily oral cadence — a pill feature was added to an injection frame.
Shotsy's growth has been largely organic — GLP-1 patients searching for "Ozempic tracker" or "Wegovy tracker" on the App Store. The brand grew with the injection GLP-1 wave. It has limited TikTok/social presence and no visible paid UA campaigns. This means GlpDay can compete on ASO without facing a heavy paid competitor.
The Shotsy price hike is a gift. Users who just switched to oral Wegovy are discovering they're paying 133% more for an app that still shows injection-first UI. GlpDay launches into exactly that frustration.
Noom is a behavioral weight loss platform with 50M users. In 2025 they launched a "GLP-1 companion mode" — essentially a marketing rebrand of their existing weight loss program with a GLP-1 label. Coaching, food logging, psychology-based behavior change. No drug-specific mechanics.
Noom's GLP-1 mode adds zero new functionality for oral pill users. There is no fasting window reminder, no protein-first nudge, no muscle protection tracking. At $70/month ($840/yr), users are paying for a generic weight loss program with a "GLP-1 friendly" badge. The conversion hook is fear, not specific utility.
Noom competes on behavior change coaching, not medication management. Its 50M user base is mostly non-GLP-1 users. The overlap with GlpDay's target user (someone specifically on oral semaglutide) is a small slice of Noom's audience. GlpDay does not need to out-coach Noom — just out-serve the specific oral GLP-1 use case at a fraction of the price.
GlpDay is purpose-built for the oral GLP-1 patient. Not a weight loss program with GLP-1 branding. 7x cheaper per year. Does the one thing Noom doesn't: helps you take your pill correctly every morning.
$69.99/yr (raised 133% from $29.99/yr). No free tier of substance. Conversion hook: refill reminders and dose streak.
Organic ASO on "GLP-1 tracker" and "Ozempic tracker" keywords. Grew with injection GLP-1 wave. Limited social presence. No significant paid UA visible.
"Price jumped from $30 to $70/yr with no new features. Pill mode is an afterthought — still shows injection-first UI."
Pill mode bolted-on$9.99/mo ($119.88/yr). Symptom tracking, mood logs, weight trends. No fasting window or pill-specific timing features.
App Store search traffic on GLP-1 companion keywords. Social media presence small. Competes primarily on symptom tracking differentiation.
"No fasting window reminder for the oral pill. Feels generic. Expensive for what it does."
No pill-timing featuresDistributed via health plans and employers. Not available as a direct consumer download. Enterprise SaaS pricing (unverified).
Health plan partnerships, employer benefit channels. Zero consumer App Store marketing. Not a direct competitor for consumer installs.
"Only available through insurance/employer. Can't just download it. Too corporate-feeling."
Not consumer-direct$70/mo or $209/yr. GLP-1 companion mode added 2025. 50M total users — GLP-1 segment is a small fraction. Upsells coaching and clinician access.
Massive TV, digital, and influencer spend. Strong brand recognition. GLP-1 mode is a PR play leveraging existing brand, not a product rebuild.
"GLP-1 mode is just a marketing wrapper. No pill-specific timing. $70/month is extortionate."
Generic weight loss wrapper$31.89/mo ($382.68/yr). "GLP-1 Program" add-on. Clinically backed weight management. WW points system unchanged — GLP-1 support is a badge.
Legacy brand, TV advertising, celebrity endorsements. Recent pivot toward GLP-1 driven by subscriber decline. Acquired a telehealth company to prescribe GLP-1 drugs directly.
"Too old-fashioned. WW points system doesn't integrate with GLP-1 mechanics. Muscle protection completely ignored."
Points system mismatch"Ozempic tracker" is owned by Shotsy. "GLP-1 tracker" is owned by Shotsy. "Wegovy pill tracker" and "oral semaglutide tracker" and "GLP pill daily" — these keywords have no dominant app. GlpDay can own the oral GLP-1 ASO category before any competitor invests in a ground-up rebuild. That window is measured in months, not years.
Category: Health & Fitness · $3.99/mo or $29.99/yr · HealthKit on-device · Built in SwiftUI / Swift 6
| Dimension | Score | Reasoning |
|---|---|---|
| Market Size | 9 / 10 | $62.8B–$94B GLP-1 drug market. 12.4M Americans on GLP-1s today, 25M projected by 2030. Weight loss app market $1.15B at 17.4% CAGR. Oral segment growing at 35% CAGR. |
| Competition Level | 7 / 10 | Existing competitors are strong in injection tracking but architecturally misaligned with oral GLP-1 needs. Shotsy is the main threat but its pill mode is bolted-on. Window is open — not wide open forever. |
| Differentiation | 9 / 10 | Pill-native UX + fasting window + protein nudges + muscle tracking is a genuine product gap, not a marketing gap. Zero competitors have all four. This is not a marginal improvement. |
| Monetization Clarity | 8 / 10 | $3.99/mo or $29.99/yr. Clear subscription model. Users paying $300–$1,500/mo for medication have zero price sensitivity at $30/yr. Conversion path is straightforward: free trial → fasting window value → upgrade. |
| Technical Feasibility | 8 / 10 | SwiftUI + Swift 6 + HealthKit + StoreKit 2. No backend required for core features. HealthKit handles health data. Single-developer buildable in 60–90 days. No AI/ML complexity required. |
| ASO Opportunity | 8 / 10 | "Wegovy pill tracker," "oral semaglutide tracker," "GLP pill daily tracker," "fasting window GLP pill" — these keywords have no dominant app. Oral GLP-1 ASO is uncontested white space right now. |
| Overall | 8.2 / 10 | GO — Strong opportunity. Oral pill era has begun, injection apps have a structural gap, first-mover pill ASO is available now. |
| Tier | Keywords | Rationale |
|---|---|---|
| High Competition | GLP-1 tracker · semaglutide app · Ozempic tracker | Worth targeting in description/keywords field for discovery — Shotsy owns these but you'll rank nearby. Include in metadata, don't bet on quick chart position. |
| Medium Competition | Wegovy pill app · GLP-1 pill reminder · oral semaglutide tracker | Realistic ranking targets within 30–60 days of launch. "Wegovy pill" and "oral semaglutide" are growing fast as oral prescriptions climb. Target these in title/subtitle. |
| Low Competition (Quick Wins) | GLP pill daily tracker · fasting window GLP pill · muscle loss prevention GLP-1 | Essentially uncontested. Niche but exactly describes the product. Users searching these terms are high-intent oral GLP-1 patients — exactly GlpDay's target user. |
| Field | Recommended | Notes |
|---|---|---|
| Title (30 chars) | GlpDay: Oral GLP-1 Tracker | 26 chars · Primary keyword "oral GLP-1 tracker" in title |
| Subtitle (30 chars) | Pill Timer & Muscle Guard | 25 chars · "Pill timer" and "muscle" surface key differentiators |
| Category | Health & Fitness | Primary. Medical as secondary if available. |
| Bundle ID | com.glpday.app |
Recommended registration |
Shotsy has the user base, brand recognition, and revenue to fund a ground-up oral GLP-1 rebuild. If they ship a real pill-native version in the next 3–6 months, the window narrows. Speed to market is the primary strategic variable. GlpDay needs to ship and acquire initial reviews before Shotsy closes the gap.
Orforglipron (Foundayo, Eli Lilly) was approved April 2026. It's taken once daily with no fasting window — an even simpler daily cadence. GlpDay's multi-drug architecture supports both oral semaglutide and orforglipron out of the gate. As orforglipron prescriptions scale, GlpDay has the only tracker built for it. Analyst projections suggest orforglipron could outpace semaglutide in oral GLP-1 market share within 24 months.
| Risk | Likelihood | Mitigation |
|---|---|---|
| Apple Health app adds GLP-1 pill tracking natively | Medium (12–24 months) | Move up-market with AI coaching, clinical integrations, or branded partnerships before Apple commoditizes basic tracking. |
| Novo Nordisk or Eli Lilly ships a branded companion app | Medium (12–18 months) | Pharma apps tend to be clinical-grade and compliant-heavy — not the consumer-friendly UX GlpDay targets. If they ship, differentiate on UX and community. |
| Prescription volume growth slower than projected | Low | +50% oral Rx growth since December 2025 is already confirmed. The trend is structural — oral GLP-1 is more convenient than injection for most users. |